YSYusuke Shono

Yusuke Shono

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yusuke Shono has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Governing the attention dividend: AI-reclaimed clinician capacity as a health policy resource

    by Yusuke Shono

    Ambient artificial intelligence (AI) is reducing documentation burden in primary care, with real but modest and variable effects: reclaimed minutes in some settings, reduced cognitive load in others, and no guarantee that either reaches patients. This article argues that the resulting capacity—the attention dividend—should be governed as a health policy resource. Without deliberate allocation, it defaults to throughput, administrative absorption, and already-advantaged patients. The article specifies the payment and care model conditions that make deliberate reallocation more feasible, including hybrid and value-based payment, continuity add-on payments, monthly per-patient care-management payments, and primary care spending floors; proposes 3 priority uses—recognition of overlooked patients, continuity, and safety-netting and reassurance; and pairs 8 allocation questions with measurable indicators, concrete policy and operational mechanisms, and accountable actors across health system leaders, payers, purchasers, primary care practices, AI vendors, regulators, and accreditors. Seven named capture mechanisms describe how the dividend fails to reach patients, each with a corrective governance response. The policy question is not whether ambient AI saves time, but whether health systems govern the capacity it returns—through mechanisms that can be named, measured, and assigned.

  • Open Access

    Clinical Validation and Machine Learning Optimization of MyCog: A Self-Administered Cognitive Screener for Primary Care Settings

    by Stephanie Ruth Young, Yusuke Shono, Katherina Hauner, Elizabeth M. Dworak, Maxwell Mansolf, Laura Curtis, Julia Yoshino Benavente, Stephanie Batio, Richard C. Gershon, Michael S. Wolf, et al.

    Importance Early detection of cognitive impairment in older adults is crucial for identifying reversible causes, managing symptoms, and enabling future planning; yet primary care settings face significant barriers to implementing effective cognitive screening. Objective To clinically validate an innovated self-administered, tablet-based cognitive screening tool (“MyCog”, adapted from the NIH Toolbox Cognitive Battery) and to develop an optimized scoring algorithm for detecting cognitive impairment in older adults during primary care visits. Design Cross-sectional clinical validation study conducted between summer 2021 and fall 2024, comparing cognitive performance between impaired and non-impaired participants using multiple machine learning approaches to identify optimal predictors of impairment. Setting Academic medical centers and community-based general population recruitment. Participants 248 adults aged 65 and older, including 70 participants with clinically diagnosed cognitive impairment (MCI or dementia), 81 participants confirmed to be cognitively intact from clinical settings, and 97 participants from the general population. Participants were predominantly White (88%) with varied educational backgrounds and a mean age of 76.3 years (SD = 6.9). Main Outcomes and Measures Sensitivity, specificity, and area under the receiver operating characteristic curve (ROC AUC) were the primary metrics used for evaluating model fit in classifying cognitive impairment of known groups from the MyCog Picture Sequence Memory and Dimensional Change Card Sort tasks. Results Across nine machine learning model classes, Picture Sequence Memory exact match score and Dimensional Change Card Sort rate-correct score were identified as the most robust predictors of cognitive impairment. The final optimized model achieved a sensitivity of 82.5% (bootstrapped 95% CI [0.733, 0.913]) and a specificity of 76.8% (bootstrapped 95% CI [0.709, 0.828]) with an ROC AUC of 0.892, comparable to traditional, long form cognitive screening measures while requiring less than 7 minutes to self-administer. Conclusions and Relevance MyCog demonstrates strong diagnostic accuracy for detecting cognitive impairment in older adults with a parsimonious model focusing on episodic memory and executive function. As a brief, self-administered screening tool that can be integrated into electronic health records, MyCog addresses key barriers to cognitive screening in primary care settings, which may help increase screening and early detection rates.

  • Open Access

    An intestinal organoid–based platform that recreates susceptibility to T-cell–mediated tissue injury

    by Yu Matsuzawa-Ishimoto, Ashley Hine, Yusuke Shono, Eugene Rudensky, Amina Lazrak, Frank Yeung, Jessica A. Neil, Xiaomin Yao, Ying-Han Chen, Thomas Heaney, et al.

    A goal in precision medicine is to use patient-derived material to predict disease course and intervention outcomes. Here, we use mechanistic observations in a preclinical animal model to design an ex vivo platform that recreates genetic susceptibility to T-cell–mediated damage. Intestinal graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic hematopoietic cell transplantation. We found that intestinal GVHD in mice deficient in Atg16L1, an autophagy gene that is polymorphic in humans, is reversed by inhibiting necroptosis. We further show that cocultured allogeneic T cells kill Atg16L1-mutant intestinal organoids from mice, which was associated with an aberrant epithelial interferon signature. Using this information, we demonstrate that pharmacologically inhibiting necroptosis or interferon signaling protects human organoids derived from individuals harboring a common ATG16L1 variant from allogeneic T-cell attack. Our study provides a roadmap for applying findings in animal models to individualized therapy that targets affected tissues.


  • Top Cited Papers

    Lactose drives Enterococcus expansion to promote graft-versus-host disease

    by C. K. Stein-Thoeringer, K. B. Nichols, A. Lazrak, M. D. Docampo, A. E. Slingerland, J. B. Slingerland, A. G. Clurman, G. Armijo, A. L. C. Gomes, Y. Shono, et al.

    Lactose can fuel GVHD: Allogeneic hematopoietic cell transplantation (allo-HCT) is used to treat certain hematopoietic malignancies, but patients have a risk of developing graft-versus-host disease (GVHD). Stein-Thoeringer et al. performed a large-scale analysis of more than 1300 patients treated with allo-HCT across four clinical centers (see the Perspective by Zitvogel and Kroemer). High levels of bacteria from the Enterococcus genus were associated with greater incidence of GVHD and mortality. Lactose appears to provide a substrate for Enterococcus growth, and patients with a lactose-malabsorption genotype had a greater abundance of Enterococcus. A lactose-free diet limited Enterococcus growth, reduced the severity of GVHD, and improved survival in gnotobiotic mouse models. Science , this issue p. 1143 ; see also p. 1077


  • Nrf2 regulates CD4+ T cell–induced acute graft-versus-host disease in mice

    by Jennifer J. Tsai, Enrico Velardi, Yusuke Shono, Kimon V. Argyropoulos, Amanda M. Holland, Odette M. Smith, Nury L. Yim, Uttam K. Rao, Fabiana M. Kreines, Sophie R. Lieberman, et al.

    Nuclear factor erythroid-derived 2-like 2 (Nrf2) is a ubiquitously expressed transcription factor well known for its role in regulating the cellular redox pathway. While there is mounting evidence suggesting a critical role of Nrf2 in hematopoietic stem cells and innate leukocytes, little is known about its involvement in T-cell biology. In this study, we identified a novel role of Nrf2 in regulating alloreactive T-cell function during allogeneic hematopoietic cell transplantation (allo-HCT). We observed increased expression and nuclear translocation of Nrf2 upon T-cell activation in vitro, especially in CD4+ donor T cells after allo-HCT. Allo-HCT recipients of Nrf2-/- donor T cells had significantly less acute graft-versus-host disease (GVHD)-induced mortality, morbidity, and pathology. This reduction in GVHD was associated with the persistence of Helios+ donor regulatory T cells in the allograft, as well as defective upregulation of the gut homing receptor LPAM-1 on alloreactive CD8+ T cells. Additionally, Nrf2-/- donor CD8+ T cells demonstrated intact cytotoxicity against allogeneic target cells. Tumor-bearing allo-HCT recipients of Nrf2-/- donor T cells had overall improved survival as a result of preserved graft-versus-tumor activity and reduced GVHD activity. Our findings not only characterized a previously unrecognized role of Nrf2 in T-cell function, but also revealed a novel therapeutic target to improve the outcomes of allo-HCT. Key points Donor T cells lacking Nrf2 demonstrate ameliorated GVHD. Absence of Nrf2 on donor cells enhanced the persistence of Helios+ nTregs in allograft recipients.


  • Production of BMP4 by endothelial cells is crucial for endogenous thymic regeneration

    by Tobias Wertheimer, Enrico Velardi, Jennifer Tsai, Kirsten Cooper, Shiyun Xiao, Christopher C. Kloss, Katja J. Ottmüller, Zeinab Mokhtari, Christian Brede, Paul Deroos, et al.

    The thymus is not only extremely sensitive to damage but also has a remarkable ability to repair itself. However, the mechanisms underlying this endogenous regeneration remain poorly understood, and this capacity diminishes considerably with age. We show that thymic endothelial cells (ECs) comprise a critical pathway of regeneration via their production of bone morphogenetic protein 4 (BMP4). ECs increased their production of BMP4 after thymic damage, and abrogating BMP4 signaling or production by either pharmacologic or genetic inhibition impaired thymic repair. EC-derived BMP4 acted on thymic epithelial cells (TECs) to increase their expression of Foxn1, a key transcription factor involved in TEC development, maintenance, and regeneration, and its downstream targets such as Dll4, a key mediator of thymocyte development and regeneration. These studies demonstrate the importance of the BMP4 pathway in endogenous tissue regeneration and offer a potential clinical approach to enhance T cell immunity.


  • Open Access

    Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium

    by Yu Matsuzawa-Ishimoto, Yusuke Shono, Luis E. Gomez, Vanessa M. Hubbard-Lucey, Michael Cammer, Jessica Neil, M. Zahidunnabi Dewan, Sophia R. Lieberman, Amina Lazrak, Jill M. Marinis, et al.

    A variant of the autophagy gene ATG16L1 is associated with Crohn’s disease, an inflammatory bowel disease (IBD), and poor survival in allogeneic hematopoietic stem cell transplant recipients. We demonstrate that ATG16L1 in the intestinal epithelium is essential for preventing loss of Paneth cells and exaggerated cell death in animal models of virally triggered IBD and allogeneic hematopoietic stem cell transplantation. Intestinal organoids lacking ATG16L1 reproduced this loss in Paneth cells and displayed TNFα-mediated necroptosis, a form of programmed necrosis. This cytoprotective function of ATG16L1 was associated with the role of autophagy in promoting mitochondrial homeostasis. Finally, therapeutic blockade of necroptosis through TNFα or RIPK1 inhibition ameliorated disease in the virally triggered IBD model. These findings indicate that, in contrast to tumor cells in which autophagy promotes caspase-independent cell death, ATG16L1 maintains the intestinal barrier by inhibiting necroptosis in the epithelium.